{"nctId":"NCT05007392","briefTitle":"A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout","startDateStruct":{"date":"2021-12-21","type":"ACTUAL"},"conditions":["Gout"],"count":451,"armGroups":[{"label":"Drug: Dotinurad + Febuxostat Matched Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Dotinurad","Other: Febuxostat Matched Placebo"]},{"label":"Drug: Febuxostat + Dotinurad Matched Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Febuxostat","Other: Dotinurad Matched Placebo"]}],"interventions":[{"name":"Dotinurad","otherNames":["FYU-981"]},{"name":"Febuxostat","otherNames":[]},{"name":"Dotinurad Matched Placebo","otherNames":[]},{"name":"Febuxostat Matched Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Gout participant (with a history of gout attack or concurrent gouty tophi) with SUA level greater than (\\>) 7.0 mg/dL in the screening phase (within 14 days prior to randomization)\n2. Male or female participant with age greater than or equal to (\\>=) 18 years at the time of informed consent\n3. Provide written informed consent signed by the participant prior to entering the study or undergoing any study procedures, indicating that they understand the purpose and procedures required for the study and are willing to participate in the study\n\nExclusion Criteria:\n\n1. Has gouty arthritis that has not resolved within 14 days prior to randomization\n2. Has secondary hyperuricemia\n3. Comorbidities with nephrolithiasis or clinical urinary calculi (example, haematuria, back pain)\n4. Evidence of clinically significant disease (example, cardiac disease: heart failure and angina unstable, respiratory, gastrointestinal, renal, or neurological disease: cerebral infarction) that in the opinion of the investigator could affect the participant's safety or interfere with the study assessments\n5. Evidence of clinical significant hepatic disease: refer to Grade 2 in the \"Seriousness Grading Criteria for Adverse Drug Reactions\" or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>3 multiple (\\*) upper limit of normal (ULN) in the screening phase\n6. Estimated glomerular filtration rate (eGFR) of less than (\\<) 30 milliliter per minute/1.73 square meters in the screening phase\n7. Systolic blood pressure of \\>=180 millimetre of mercury (mmHg) or diastolic blood pressure of \\>=110 mmHg in the screening phase\n8. Hemoglobin A1c National Glycohemoglobin Standardization Program (NGSP) value of \\>=8.4 percent (%) in the screening phase\n9. Hypersensitivity to the study drugs (dotinurad or febuxostat) or their excipients, or all of urine alkalinizer (potassium citrate/sodium citrate hydrate compound preparations)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Serum Uric Acid (SUA) Level <=6.0 mg/dL at Week 24 (LOCF)","description":"Percentage of participants with SUA level less than or equal to (\\<=) 6.0 milligrams per deciliter (mg/dL) at Week 24 was reported. In case the SUA level was missing, this data was compensated by the last observation carried forward (LOCF) method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.1","spread":null},{"groupId":"OG001","value":"73.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SUA Level <=6.0 mg/dL at Week 12 (LOCF)","description":"Percentage of participants with SUA level \\<=6.0 mg/dL at Week 12 was reported. In case the SUA level was missing, this data was compensated by the LOCF method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.5","spread":null},{"groupId":"OG001","value":"55.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SUA Level <=6.0 mg/dL at Weeks 4, 8, 12, 16, 20 and 24","description":"Percentage of participants with SUA level \\<=6.0 mg/dL at Weeks 4, 8, 12, 16, 20 and 24 was reported. Data was reported for observed participants at specified visits.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3","spread":null},{"groupId":"OG001","value":"27.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.6","spread":null},{"groupId":"OG001","value":"62.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.8","spread":null},{"groupId":"OG001","value":"56.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.7","spread":null},{"groupId":"OG001","value":"84.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.7","spread":null},{"groupId":"OG001","value":"83.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.2","spread":null},{"groupId":"OG001","value":"78.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Percent Reduction From Baseline in SUA Level at Weeks 4, 8, 12, 16, 20 and 24","description":"Mean percent reduction from baseline in SUA level at Weeks 4, 8, 12, 16, 20 and 24 was reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.43","spread":"13.200"},{"groupId":"OG001","value":"27.43","spread":"14.754"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.06","spread":"14.018"},{"groupId":"OG001","value":"39.10","spread":"18.931"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.06","spread":"15.383"},{"groupId":"OG001","value":"38.62","spread":"17.305"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.13","spread":"16.016"},{"groupId":"OG001","value":"51.47","spread":"18.542"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.71","spread":"15.728"},{"groupId":"OG001","value":"50.22","spread":"20.714"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.28","spread":"16.907"},{"groupId":"OG001","value":"48.07","spread":"23.243"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in SUA Level at Weeks 4, 8, 12, 16, 20 and 24","description":"Mean change from baseline in SUA level at Weeks 4, 8, 12, 16, 20 and 24 was reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.60","spread":"1.457"},{"groupId":"OG001","value":"-2.70","spread":"1.508"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.62","spread":"1.597"},{"groupId":"OG001","value":"-3.80","spread":"1.973"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.52","spread":"1.691"},{"groupId":"OG001","value":"-3.78","spread":"1.817"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.44","spread":"1.731"},{"groupId":"OG001","value":"-5.05","spread":"2.078"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.52","spread":"1.757"},{"groupId":"OG001","value":"-4.92","spread":"2.201"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.20","spread":"1.800"},{"groupId":"OG001","value":"-4.71","spread":"2.415"}]}]}]},{"type":"SECONDARY","title":"Mean SUA Level at Baseline, Weeks 4, 8, 12, 16, 20 and 24","description":"Mean SUA level at Baseline, Weeks 4, 8, 12, 16, 20 and 24 was reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.65","spread":"1.426"},{"groupId":"OG001","value":"9.67","spread":"1.451"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.07","spread":"1.432"},{"groupId":"OG001","value":"6.93","spread":"1.447"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.01","spread":"1.372"},{"groupId":"OG001","value":"5.80","spread":"1.857"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.12","spread":"1.546"},{"groupId":"OG001","value":"5.88","spread":"1.708"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.24","spread":"1.605"},{"groupId":"OG001","value":"4.65","spread":"1.776"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.14","spread":"1.467"},{"groupId":"OG001","value":"4.76","spread":"1.900"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.49","spread":"1.575"},{"groupId":"OG001","value":"5.00","spread":"2.296"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":225},"commonTop":["Gouty arthritis","COVID-19","Alanine aminotransferase increased","Hepatic function abnormal","Upper respiratory tract infection"]}}}